Discovers and develops gene and cellular therapies. Provides disease-modifying therapeutics. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 245.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 37% of them.
Analysts' average target sits 169% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
The company sells $9.7M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $250.6M against $9.7M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, PGEN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PGEN’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (37/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.